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MYCN is an oncogenic driver of childhood neuroblastoma, a frequently lethal pediatric tumor. In a recent
paper in Science Translational Medicine, Chanthery and colleagues demonstrate that PI3K inhibition leads
to the dual therapeutic benefits of enhanced MYCN degradation and loss of a paracrine angiogenic signal
mediated by MYCN.Despite decades of ever-improving
outcomes across diverse pediatric
cancers, neuroblastoma has remained a
frustrating clinical entity. Most children
are diagnosed with tumors that harbor
genetic and biological features highly
correlated with a poor treatment out-
come. Current therapy for such high-risk
patients includes dose-intensive chemo-
therapy, radiotherapy, and retinoids.
Though there have been recent impres-
sive translational successes for this
tumor, such as immunotherapy using
an antibody targeting cell-surface GD2
given with immunostimulatory cytokines
(Yu et al., 2010), 3 year relapse free
survival estimates for high-risk disease
remain under 50%.
Further compounding the frustration is
the fact that the genome of neuroblas-
toma is one of the most comprehensively
characterized among pediatric cancers,
but it has not yet led to more effective
treatment. The recent discovery that the
ALK receptor tyrosine kinase is constitu-
tively activated in 10% of neuroblas-
tomas (Mosse´ et al., 2008) provides onesuch therapeutic opportunity, as ALK
inhibitors have been in development due
to the involvement of this kinase in a
subset of non-small-cell lung cancers
and anaplastic lymphomas. First genera-
tion ALK inhibitors such as crizotinib are
already in Phase 2 trials for children with
relapsed or refractory neuroblastoma
and may make their way soon into upfront
therapy for those patients with ALK-
mutated tumors.
Contrast that withMYCN, the only other
bona fide oncogene yet discovered in
neuroblastoma that was initially identified
almost 30 years ago (Brodeur et al., 1984).
Despite this lead-time and a great deal of
effort, no therapeutic has yet emerged to
be able to target this clear oncogenic
driver of the most aggressive subset
of neuroblastomas. MYCN, which is a
homolog of the MYC proto-oncogene, is
somatically amplified in the tumor cells
of 20% of neuroblastoma patients (and
in 40% of those with a high-risk pheno-
type). MYCN amplification is indepen-
dently correlated with advanced stage
disease and poor outcome and thereforeis used worldwide in risk classification
algorithms. Moreover, genetically engi-
neered mouse models with MYCN ex-
pression targeted to neural crest tissue
develop tumors that resemble human
neuroblastoma (Weiss et al., 1997). MYC
proteins, including MYCN, serve pleio-
tropic roles in malignancy, such as
altering metabolic programs, supporting
angiogenesis, promoting self-renewal
and ‘‘stemness,’’ and driving proliferation
while inhibiting differentiation.
ALK as a kinase is a pharmacologically
tractable target, and a wealth of experi-
ence suggests that inhibition of activated
kinases can lead to clinically impressive
tumor responses. MYCN, in contrast,
has long been seen as a problematic
therapeutic target, as inactivating a highly
abundant nuclear transcription factor that
operates through a network of protein-
protein interactions is pharmacologically
daunting. Still, tumors are remarkably
heterogeneous and cancer cells are
remarkably adaptive. Resistance to tar-
geted therapeutics can be efficiently
selected for, especially when cells haveFebruary 14, 2012 ª2012 Elsevier Inc. 145
Figure 1. Neuroblast-Intrinsic and -Extrinsic Therapeutic Effects of the Dual PI3K/mTOR
Inhibitor NVP-BEZ235
MYCN (and MYC, when similarly dysregulated) induce vasculogenesis via secretion of VEGF and other
angiogenic factors. Tumor-associated angiogenesis is similarly supported by paracrine signaling via
VEGF downstream of MYCN. NVP-BEZ235 impacts tumorigenesis through inhibition of PI3K and
mTOR kinases, through PI3K inhibition-mediated degradation of MYCN, through GSK3b-mediated phos-
phodegradation pathways, and through direct anti-angiogenic effects on tumor-associated endothelial
cells themselves. Not shown are effects attributable to mTOR inhibition, and pleiotropic effects realized
by antagonism of MYCN activity in neuroblasts.
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pathways to compensate for the one
being targeted, as is often the case with
apical kinases such as ALK. MYC
proteins, however, are unique in that their
actions are largely non-redundant. In
many experimental systems, the only
gene products that can substitute for
MYC are otherMYC homologs. Emerging
data using animal models also suggest
that toxicity associating with MYC inhibi-
tion might not be as problematic as
initially feared (Soucek et al., 2008). So
MYC remains a compelling therapeutic
target for neuroblastoma and many other
cancers (Delmore et al., 2011).
It is therefore of great interest that
a recent paper in Science Translational
Medicine demonstrates the benefits of
inhibiting PI3K and mTOR signaling with
the small molecule NVP-BEZ235 in
complementarymodels of neuroblastoma
(Chanthery et al., 2012). Neuroblastomas
are richly vascular tumors, particularly
those with MYCN amplification, and it
has long been inferred that MYCN may
modulate tumor angiogenesis via regula-
tion of VEGF expression, as has been
more formally demonstrated for MYC
(Baudino et al., 2002). Indeed, it has been
shown that PI3K/mTOR blockade leads
to destabilization of MYCN and commen-146 Cancer Cell 21, February 14, 2012 ª2012surate reduction in VEGF secretion, along
with inhibition of neuroblastoma progres-
sion in murine models (Chesler et al.,
2006). One critical component lacking
up until now had been the relative contri-
butions of inhibiting PI3K/mTOR in the
tumor cells themselves, as opposed to in
other cells within the tumor microenviron-
ment. That is, is the observed anti-tumor
activity mediated by tumor cell intrinsic
or extrinsic mechanisms, or both?
Chanthery et al., (2012) demonstrate
that NVP-BEZ235 inhibits neuroblast
proliferation in vitro and that this effect is
more pronounced in those cell lines with
MYCN amplification and overexpression.
They then corroborate an impact on
tumor progression using both a neuro-
blastoma xenograft model (in which
contributions of the immune compart-
ment are lacking) as well as a MYCN-
dependent transgenic model (recapitu-
lating a MYCN ‘‘amplified’’ tumor arising
at its autochthonous site). Though tumor
regressions were not described, there
was inhibition of tumor growth in both
models, attributed to both reductions
in tumor-associated vascular density
and neuroblast proliferation. MYCN was
markedly reduced in treated tumors, and
evidence for both PI3K and mTOR inhibi-
tion was demonstrated, supporting theElsevier Inc.notion that PI3K inhibition led to derepres-
sion of GSK3b with resultant Thr58 phos-
phorylation and destabilization of MYCN.
The authors used a series of elegant
experiments to then decipher the contri-
butions of the tumor compartment by
introducing wild-type MYCN or a Thr58
mutant MYCN that is resistant to Thr58-
mediated destabilization into a neuroblas-
toma cell line with undetectable MYCN.
These models allow the investigators to
attribute tumor-cell autonomous effects
of NVP-BEZ235 to MYCN degradation
by correlating MYCN stability, VEGF
secretion, and recruitment of HUVECcells
in endothelial migration assays. The
impact of NVP-BEZ235 onMYCN stability
and proliferation was reduced in cells
expressing the Thr58 mutant MYCN.
Importantly, VEGF secretion and HUVEC
migration also was shown to be substan-
tially MYCN-dependent, supporting a
paracrine role downstream of MYCN.
Indeed, direct knock-down of MYCN or
indirect upregulation via knock-down of
HUWE1 (an E3-ligase that degrades
phosphorylated MYCN) led to commen-
surate changes in MYCN stability, VEGF
secretion, and HUVEC recruitment,
underscoring a prominent role for MYCN
in this paracrine activity. NVP-BEZ235
clearly had a direct impact on endothelial
cells themselves. However, this suggests
the anti-angiogenic effects seen in vivo
were both tumor cell intrinsic and extrinsic
(Figure 1).
It should be noted that the impact of
NVP-BEZ235 (via PI3K/mTOR inhibition)
was more modest in most of these
assays than was knock-down of MYCN,
suggesting that its impact on MYCN
was suboptimal. Still, an agent that
targets the predominant oncogenic driver
in this malignancy to impact diverse
MYCN-mediated functions and represses
tumor-associated angiogenesis directly
through effects on endothelial cells and
indirectly through paracrine mediated
effects of tumor cells is certainly worth
exploring clinically. Chanthery et al.,
(2012) demonstrate compelling indirect
evidence that VEGF is the intermediate
in this paracrine process but do not
directly demonstrate this either by VEGF
knock-down or by using available VEGF
antagonists in their assays. Might PI3K/
mTOR inhibition synergize with VEGF
antagonists to potentiate these anti-
angiogenic effects? Also, it is fair to
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restricted to neuroblastomas with MYCN
amplification, as surmised, or might oper-
ate similarly through MYC when this
homolog is deregulated. In high-risk
neuroblastomas that lack MYCN amplifi-
cation, MYC is frequently deregulated
(Westermann et al., 2008), suggesting
some degree of MYC or MYCN augmen-
tation may be essential for the high-risk
phenotype. This was not directly tested
because the available transgenic model
for this tumor mimicsMYCN amplification
as an oncogenic driver and no MYCN
non-amplified tumor xenografts were
explored. Though elucidation of a novel
MYCN-directed therapeutic is significant
enough, the impact may be further broad-
ened to a greater proportion of patients
with high-risk neuroblastoma should
MYC serve a similar role, which is aworthypursuit, and may extend the relevance of
these findings to all human cancers that
usurp MYC signaling as an essential
component of sustaining the malignant
phenotype.
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The success of theRAFprotein kinase inhibitor vemurafenib for the treatment ofBRAFmutantmetastaticmela-
noma has produced another poster child for the promise of personalized medicine. However, the results of
a recent study also reveal unexpected pitfalls in the application of signal transduction-targeted therapies.The era of personalized cancer medicine
is upon us. The cancer patient’s genome
can now be interrogated for specific
genetic alterations to guide the applica-
tion of therapies specifically targeted to
those alterations. A dramatic therapeutic
advance in this area is the BRAF-selective
inhibitor vemurafenib, which has pro-
vided a significant improvement in overall
survival compared to the previous stan-
dard of care for metastatic melanoma
(Chapman et al., 2011). However, recent
findings with vemurafenib and other pro-
tein kinase inhibitors demonstrate that
the new era of signal transduction-tar-
geted therapies is handicapped by some
of the same issues that have plagued
traditional cytotoxic drugs.One key distinction between targeted
versus cytotoxic therapies is decreased
normal cell toxicity. Symptoms such as
the classic myelosuppression associated
with many cytotoxic antineoplastics are
not as limiting with targeted agents,
whose therapeutic effects are typically
achievable at doses lower than those
conferring myelosuppression or other
dose-limiting toxicities. However, rapidly
acquired cancer cell resistance shortens
the duration of treatment response. For
example, although the initial response
to vemurafenib is impressive, with a re-
sponse rate of 50% and significant sur-
vival benefit, tumor resistance usually
occurs within 2–18 months of initial treat-
ment. Multiple mechanisms of resistancehave been described, including muta-
tional activation of NRAS or receptor tyro-
sine kinase-mediated activation of RAS,
both leading to CRAF-dependent activa-
tion of MEK-ERK signaling (Figure 1)
(Johannessen et al., 2010; Nazarian et al.,
2010). Thus, as for cytotoxic drugs, com-
binations of targeted therapies will be
needed, both to enhance the initial re-
sponse and to reduce the subsequent
onset of drug resistance. Such com-
binations may also have advantages in
blocking the existing tumor without
inducing or allowing new ones to appear.
That chemotherapy can both cure and
cause cancer is not a new concept. Con-
ventional cytotoxic chemotherapy has
long been known to contribute to theFebruary 14, 2012 ª2012 Elsevier Inc. 147
